Skip to main content

Advertisement

Log in

Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

This study was to investigate the value of 10 serum inflammatory cytokines for predicting clinical response to celecoxib in ankylosing spondylitis (AS) patients.

Methods

Totally, 103 active AS patients who underwent celecoxib treatment for 12 weeks were enrolled. Then, pre-treatment serum TNF-α, IL-1β, IL-6, IL-8, IL-17A, IL-21, IL-23, IL-32, ICAM-1, and VEGF were detected by enzyme-linked immunosorbent assay. Besides, the ASAS 20 response was assessed at week 2 (W2), week 6 (W6), and week 12 (W12). Based on the ASAS 20 response at W12, patients were divided into responders and non-responders.

Results

After celecoxib treatment, 53 (51.3%), 58 (56.3%), and 60 (58.3%) patients achieved ASAS 20 response at W2, W6, and W12, respectively. Furthermore, IL-1β (P = 0.019), IL-6 (P = 0.004), and IL-17A (P = 0.007) levels were higher, while TNF-α (P = 0.086), IL-8 (P = 0.143), IL-21 (P = 0.687), IL-23 (P = 0.329), IL-32 (P = 0.216), ICAM-1 (P = 0.119), and VEGF (P = 0.732) levels were similar in responders compared with non-responders. Subsequent multivariate logistic regression analysis revealed that among these inflammatory cytokines, only IL-6 (P = 0.019) independently predicted higher ASAS 20 response to celecoxib at W12, and it had a fair value for predicting ASAS 20 response to celecoxib at W12 (area under the curve: 0.666, 95% confidence interval: 0.561–0.771) by receiver-operating characteristic curve analysis.

Conclusion

Serum IL-1β, IL-6, and IL-17A serve as indicators for predicting clinical response to celecoxib in AS patients, which may assist with the optimization of personalized treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390

    Article  Google Scholar 

  2. Bidad K, Gracey E, Hemington KS et al (2017) Pain in ankylosing spondylitis: a neuro-immune collaboration. Nat Rev Rheumatol 13(7):410–420

    Article  CAS  Google Scholar 

  3. Huang F, Gu J, Liu Y et al (2014) Efficacy and safety of celecoxib in Chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp 76:126–133

    Article  CAS  Google Scholar 

  4. Tam LS, Gu J, Yu D (2010) Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 6(7):399–405

    Article  Google Scholar 

  5. Poddubnyy DA, Song IH, Sieper J (2008) The safety of celecoxib in ankylosing spondylitis treatment. Expert Opin Drug Saf 7(4):401–409

    Article  CAS  Google Scholar 

  6. McCormack PL (2011) Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71(18):2457–2489

    Article  CAS  Google Scholar 

  7. van der Linden S (2008) Issues in the treatment of ankylosing spondylitis with non-steroidal anti-inflammatory drugs. Wien Med Wochenschr 158(7–8):195–199

    Article  Google Scholar 

  8. Sveaas SH, Berg IJ, Provan SA et al (2015) Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 44(2):118–124

    Article  CAS  Google Scholar 

  9. Sezer U, Erciyas K, Pehlivan Y et al (2012) Serum cytokine levels and periodontal parameters in ankylosing spondylitis. J Periodontal Res 47(3):396–401

    Article  CAS  Google Scholar 

  10. Wen JT, Zhang DH, Fang PF et al (2017) Role of Th1/Th2 cytokines in the diagnosis and prognostic evaluation of ankylosing spondylitis. Genet Mol Res 16(1)

  11. Yan Y, Guo TM, Zhu C (2018) Effects of nonsteroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis. Biochem Cell Biol 96(4):450–456

    Article  CAS  Google Scholar 

  12. Pan JE, Xiong FL, Chen G et al (2017) Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: a comparative study. Biomed Pharmacother 95:1549–1555

    Article  CAS  Google Scholar 

  13. Sieper J, Rudwaleit M, Baraliakos X et al (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68(Suppl 2):ii1–i44

    Article  Google Scholar 

  14. Anderson JJ, Baron G, van der Heijde D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886

    Article  CAS  Google Scholar 

  15. Stone MA, Payne U, Pacheco-Tena C et al (2004) Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 63(1):84–87

    Article  CAS  Google Scholar 

  16. Falkenbach A, Herold M, Wigand R (2000) Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year? Rheumatol Int 19(4):149–151

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chao Ning.

Ethics declarations

The approval of this study was obtained from the Institutional Review Board of our hospital. Written informed consents were collected from all enrolled patients.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Ning, C., Zhou, H. et al. Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients. Ir J Med Sci 190, 631–638 (2021). https://doi.org/10.1007/s11845-020-02366-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-020-02366-5

Keywords

Navigation